Categories
Featured Exclusive
For patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC), effective treatment options with minimal toxicity remain limited. In this interview with i3 Health, Julien Mazières, MD, PhD, Professor of Respiratory Medicine at Toulouse University Hospital, discusses his collaborative research finding that atezolizumab increases long-term overall survival com...
Top Oncology Stories
Tuesday, November 24, 2020
For patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC), effective treatment options with minimal toxicity remain limited. In this interview with i3 Heal...
Monday, November 23, 2020
In a meta-analysis now published in JAMA Network Open, elevated plasma circulating tumor DNA (ctDNA) was linked to an increased risk of relapse in patients with metastatic and locally advanced breast ...
Friday, November 20, 2020
The FDA recently approved new doses of durvalumab (Imfinzi®, AstraZeneca) for the treatment of patients with previously treated advanced urothelial carcinoma and unresectable stage III non-small...
Thursday, November 19, 2020
In patients who have been diagnosed with T1 N0 M0 triple-negative breast cancer (TNBC), age plays a role in whether chemotherapy or radiotherapy will lead to better outcomes for overall survival and b...
Wednesday, November 18, 2020
In individuals without cancer, vitamin D supplementation may decrease the risk of developing advanced cancer, especially for those with a normal body mass index (BMI), according to a recent analysis o...
Tuesday, November 17, 2020
Patients who undergo baseline lung cancer screening are less likely to adhere to screening recommendations compared with the screening rates of patients who participate in randomized clinical trials, ...
Most Popular
Expert Perspectives
For patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC), effective treatment options with minimal toxicity remain limited. In this interview with i3 Health, Julien Mazières, MD, PhD, Professor of Respira...
Results of a new study presented at American Society of Radiation Oncology (ASTRO) 2020 reveal that adjuvant radiotherapy (aRT) significantly increased the risk of late toxicity compared with salvage radiotherapy (sRT). Lead author of the study, Paul...
The FDA recently approved nivolumab/ipilimumab for the first-line treatment of malignant pleural mesothelioma, marking the second FDA approval for this condition and the first approval in the past 16 years. In this interview, Paul Baas, MD, PhD, prin...
A recent study presented by Ming Shi, MD, PhD and colleagues at ESMO Virtual Congress 2020 found that hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin, fluorouracil, and leucovorin (FOLFOX) yield more effective results in patients with ...
While antifungal prophylaxis can effectively prevent invasive fungal infections in patients with hematologic diseases, there is no consensus on which prophylactic agents provide the greatest benefit for different patient populations. In a meta-analys...
Original Research
Pre-activity assessment data from i3 Health's nursing continuing professional development (NCPD) activity "Understanding and Optimizing CAR T-Cell Therapy for Patients With B-Cell Malignancies" has revealed significant baseline knowledge gaps regardi...
At the 67th Society of Government Service Urologists (SGSU) Kimbrough Urological Seminar, held from January 15th to 19th, 2020, in Charlotte, North Carolina, i3 Health conducted a survey of participants regarding the formats in which they wished to r...
Pre-activity assessment data from i3 Health's continuing medical education (CME)/continuing nursing education (CNE) activity "Optimizing the Management of Advanced Cervical Cancer With Checkpoint Inhibitor Therapy" has revealed significant baseline k...
Due to the increase in treatment options for castration-resistant prostate cancer (CRPC) in recent years, some confusion exists over the optimal therapeutic approach. A number of factors must be considered in CRPC treatment, including patient health ...
Optimal management of carcinoid syndrome in patients with neuroendocrine tumors poses a challenge, due to the fact that the primary symptoms of carcinoid syndrome are associated with more common diseases. Because timely recognition is difficult, symp...
